

PRESS RELEASE

GENOPOLE PLAYERS OSSEOMATRIX, YNSECT AND GÉNÉTHON: LAUREATES OF THE "WORLDWIDE INNOVATION 2030 CHALLENGE"

Évry (France), 4 May 2015

The companies OsseoMatrix and Ynsect and the laboratory Généthon were among the 16 laureates of the second phase of the Worldwide Innovation 2030 Challenge, an initiative of the French State launched in 2013 to foster the emergence of innovative projects in sectors strategic for France. Representatives of the three Genopole entities were received April 28th by President of France François Hollande and Innovation 2030 Commission Chair Anne Lauvergeon.

The purpose of the second phase of the Innovation 2030 Challenge is to identify, among the 110 first-phase laureates named in 2014, those projects holding particular promise for France and reward them with financial support ranging from 1 to 3 million euros earmarked for risk reduction.

Thus, the advancement to the second phase by OsseoMatrix and Ynsect is a clear demonstration of the technological and economic potential of their projects, respectively in individualized medicine and alternative protein production. Not to be outdone, the phase-two recognition of Généthon is a testament to its leading expertise in gene therapy.

OsseoMatrix employs a patented direct 3D impression process to create custom-tailored synthetic bone implants to address craniomaxillofacial, dental or orthopedic bone loss. *"This phase-2 Innovation 2030 prize is an honor and recognition for our team, and furthermore an illustration of the importance of personalized medicine in the management of bone loss,"* declares OsseoMatrix CEO Didier Nimal. *"With this award, we will be able to recruit new employees and accelerate the deployment of the industrial production pilot for our implants."*

Ynsect is creating a novel approach to the industrial production and transformation of insects to address the dietary challenges of the near future. *"The support provided by France in this second phase of the Challenge is an honor for the entire team,"* comments Ynsect President and R&D Director Antoine Hubert. *"It also illustrates how scientists and decisions makers have come to understand that insects are a viable solution to the challenge of relocating protein production to France and Europe."*

Généthon, a laboratory founded by the AFM-Téléthon, is developing a process for the industrial production of gene therapy vectors for the treatment of both rare and frequent diseases. *"We are very proud of this prize and feel that it recognizes our laboratory's expertise in gene therapies and their industrial applications,"* underlines Généthon CEO Frédéric Révah. *"Généthon is a manifestation of the excellence of French research and a motor for the crucial development of an innovative biotherapies industry that benefits patients and brings high economic added value."*



Didier Nimal, CEO of OsseoMatrix, explains a 3D impression process for bone implants to Minister of Digital Affairs Axelle Lemaire, Innovation 2030 Commission Chair Anne Lauvergeon, and President of France François Hollande (Image taken from Élysée Palace video).

Genopole press contact: Véronique Le Boulc'h – veronique.leboulch@genopole.fr - +33 (0)1 60 87 44 98

About OsseoMatrix

Created in 2009 by Dr Didier Nimal, OsseoMatrix conceives and manufactures custom-tailored synthetic bone implants to address craniomaxillofacial, dental or orthopedic bone loss. Made with a patented process, OsseoMatrix's micro-porous implants have characteristics close to

those of natural bone. They reduce surgical mutilation and guide bone healing. Osseomatrix coordinates a program of the French National Research Agency that brings together several partners (CEA, Ecole des Mines de Saint Etienne, CNRS, etc.). The company is a member of the Medicen Paris région competitiveness cluster and the European Ceramics Center. Osseomatrix is a laureate of the Competition for Business Creation in Innovative Technologies of the French Ministry for Higher Education and Research (2008 and 2010), the Siemens Innovation Award (2012), and the Worldwide Innovation 2030 Challenge (2014 and 2015). The company is supported by BPI France, the Ile-de-France Administrative Region, and the Essonne Departmental Council.

Press contact: contact@osseomatrix.com - www.osseomatrix.com

About Ynsect

Created in late 2011 by Antoine Hubert, Jean-Gabriel Levon, Fabrice Berro and Alexis Angot, Ynsect is a company specialized in the industrial production and transformation of insects for nutrition and green industry. In 2014, Ynsect developed an insect production pilot at Genopole in Évry, France. The company leads large-scale R&D programs in collaboration with the leading French and European academic and reference centers (CEA, INRA, CNRS, IFREMER, AgroParisTech, IRSTEA, Wageningen University, etc.). Supported by BPI France and the Ile-de-France Administrative Region, Ynsect is an active member of several competitiveness clusters (Industries Agro Ressources, Vitagora, etc.). The company is a laureate of the Worldwide Innovation 2030 Challenge (2014 and 2015) and the Cleantech Open Global Forum in San Francisco.

Press contact: media@ynsect.com - www.ynsect.com

About Généthon

Généthon was founded by AFM-Téléthon, the French muscular dystrophy association. Its mission is to bring innovative gene therapy treatments to patients. Building upon its history as a pioneer in the decryption of the human genome, Généthon is today a leading international center for the research and development of gene therapies for rare diseases. The laboratory benefits from a more than 200-strong staff of researchers, physicians, regulatory affairs professionals and other specialists. Généthon has the world's largest GMP gene therapy production site: Généthon Bioprod. In 2012, Généthon was the first non-profit laboratory to receive the prestigious Prix Galien for pharmaceutical research (France).

www.genethon.fr

About Genopole

Genopole is the leading French biopark dedicated to research in genetics and biotechnologies for healthcare and the environment. Genopole unites 20 research laboratories, 81 biotech companies and 21 technical platforms as well as university training programs (Evry-Val-d'Essonne University). Its objectives are to favor the development of research in genomics, post-genomics and other related fields, assure the transfer of resulting technology to the industrial sector, establish academic-level training programs for these fields, and finally to create and support biotech companies. Genopole is funded mainly by the Ile-de-France Regional Council (30%), the Essonne Department Council (26.5%) and the French State (15.7%).

www.genopole.fr